Biogen (NASDAQ:BIIB) executives said the company ended 2025 “slightly above the upper end” of its guidance, pointing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results